sfc7 Antibody

What is FBXW7 and why is antibody selection critical for studying this protein?

FBXW7 (F-box and WD repeat domain-containing 7) is the substrate recognition component of the E3 ubiquitin ligase SCF complex that controls levels of critical proteins including CYCLINE, c-MYC, and HIF1α. As a tumor suppressor gene, mutations in FBXW7 are frequently associated with tumorigenesis . The protein exists in three major isoforms (α, β, and γ) with distinct subcellular localizations and functions. Each isoform has a characteristic molecular weight: FBXW7α appears at 110kDa, FBXW7β at 68-70kDa, and FBXW7γ at 65-66kDa .

Antibody selection is particularly critical for FBXW7 research because recent studies have revealed that some commonly used FBXW7 antibodies fail to detect their intended targets. For example, research has demonstrated that a widely used C-terminus FBXW7 antibody consistently detected a nonspecific 64kDa band rather than any of the three FBXW7 isoforms, potentially compromising research findings . This highlights the need for thorough antibody validation before conducting experiments.

How should researchers approach FBXW7 antibody validation before experimental use?

A multi-step validation approach is essential:

• Overexpression verification: Transfect cells with tagged FBXW7 constructs (e.g., Flag-tagged isoforms) and compare detection between your FBXW7 antibody and an antibody against the tag. This approach clearly established in research that N-terminus directed antibodies reliably detected FBXW7α at 110kDa while some C-terminus antibodies failed to detect any isoform .

• Molecular weight confirmation: Verify that detected bands correspond to expected molecular weights of FBXW7 isoforms (110kDa for α, 68-70kDa for β, and 65-66kDa for γ). Be cautious of bands at unexpected sizes, such as the nonspecific 64kDa band detected by some commercial antibodies .

• Functional validation: Test whether detected bands respond to conditions that should affect FBXW7 levels. For example, treatment with proteasome inhibitors like MG132 should increase abundance of true FBXW7 bands, as demonstrated in research where MG132 increased the 110kDa FBXW7α band but had no effect on nonspecific bands .

• Immunoprecipitation cross-validation: Perform immunoprecipitation with your FBXW7 antibody and detect with another antibody targeting a different epitope, or with a tag-specific antibody for tagged constructs .

Thorough validation is particularly important as published research has demonstrated that antibody unreliability can lead to misinterpretation of results in FBXW7 studies .

What is the significance of epitope selection when choosing FBXW7 antibodies?

Epitope selection is crucial for FBXW7 antibody performance due to the protein's structural characteristics:

• N-terminus vs. C-terminus antibodies: Research has shown that FBXW7α N-terminus directed antibodies reliably detect the protein under standard Western blotting conditions, while some C-terminus antibodies fail to detect any FBXW7 isoforms despite targeting a region common to all isoforms .

• Structural basis for differential detection: Alpha Fold structure prediction analysis reveals that the FBXW7α N-terminal domain forms a long, linear and disorganized loop that closely resembles the linear epitope used to generate antibodies. In contrast, the C-terminus forms a highly organized 3D tertiary structure consisting of β-sheets that may be disrupted during denaturation, potentially explaining why some C-terminus antibodies fail in Western blotting .

• Isoform specificity considerations: When studying specific FBXW7 isoforms, epitope selection determines detection specificity. N-terminus antibodies are isoform-specific (detecting only FBXW7α), while properly validated C-terminus antibodies should theoretically detect all isoforms .

• Native vs. denatured detection: Some antibodies may only recognize proteins in specific conformational states. Research demonstrated that certain C-terminus FBXW7 antibodies failed to work in both denaturing Western blots and native immunoprecipitation conditions .

Understanding these epitope characteristics is essential for selecting antibodies that will reliably detect FBXW7 in your experimental system.

How can researchers optimize Western blotting protocols specifically for FBXW7 detection?

Based on published research findings, the following optimizations are recommended for reliable FBXW7 detection by Western blotting:

• Sample preparation considerations:

  • Include proteasome inhibitors (e.g., MG132) in lysis buffers to prevent FBXW7 degradation during extraction

  • Use denaturing lysis buffers containing SDS and reducing agents for N-terminus-directed antibodies

  • Consider running parallel samples with different extraction methods if using multiple antibodies

• Gel electrophoresis parameters:

  • Use lower percentage gels (7-8% acrylamide) to better resolve the high molecular weight FBXW7α (110kDa)

  • Run gels at controlled voltage (80-100V) through stacking and 120-150V through resolving gel for optimal resolution

  • Load positive controls (cells transfected with tagged FBXW7 constructs) alongside experimental samples

• Antibody selection and validation:

  • For FBXW7α detection, prioritize validated N-terminus antibodies that consistently detect the 110kDa band

  • For all isoforms, consider using tagged constructs with anti-tag antibodies as a reliable alternative

  • Run parallel blots with different antibodies to cross-validate detection patterns

• Signal optimization strategies:

  • Extend primary antibody incubation to overnight at 4°C for improved sensitivity

  • Optimize blocking conditions based on specific antibody recommendations

  • Consider signal enhancers for detection of low-abundance endogenous FBXW7

Research has shown that failure to optimize these parameters can lead to misinterpretation of results, particularly when antibodies detect nonspecific bands instead of actual FBXW7 protein .

What controls are essential when studying FBXW7 across different experimental conditions?

When studying FBXW7 across various experimental conditions, researchers should incorporate these essential controls:

Research demonstrates that inadequate controls have led to misinterpretation of FBXW7 expression patterns in previous studies, highlighting their critical importance .

How should researchers design immunoprecipitation experiments to study FBXW7 interactions?

For successful FBXW7 immunoprecipitation experiments, consider these research-based recommendations:

• Antibody selection for immunoprecipitation:

  • Based on published findings, N-terminus antibodies show superior performance for immunoprecipitating FBXW7α compared to some C-terminus antibodies

  • For studying multiple isoforms, epitope-tagged constructs with anti-tag antibodies provide reliable results

  • Always validate antibody performance in immunoprecipitation before proceeding with interaction studies

• Optimization of extraction conditions:

  • For native interactions: Use buffers containing mild detergents (0.5-1% NP-40 or Triton X-100) with protease inhibitors

  • For studying ubiquitination: Consider denaturing conditions (1% SDS, followed by dilution before antibody addition)

  • Always include proteasome inhibitors to prevent degradation during extraction

• Critical experimental controls:

  • IgG control immunoprecipitations to identify nonspecific binding

  • Input controls (5-10% of lysate) for comparison with immunoprecipitated samples

  • Parallel immunoprecipitations with different antibodies to cross-validate results

• Detection strategies for interaction partners:

  • Probe for known FBXW7 binding partners as positive controls

  • For novel interactions, consider mass spectrometry analysis

  • When using tagged constructs, immunoprecipitate with either FBXW7 antibody or tag antibody and detect with the other

Research has demonstrated successful immunoprecipitation of FBXW7α using N-terminus antibodies, while some C-terminus antibodies failed to immunoprecipitate the protein despite theoretically targeting epitopes present in all isoforms .

How should researchers interpret unexpected molecular weight bands when using FBXW7 antibodies?

When encountering unexpected bands with FBXW7 antibodies, follow this systematic interpretation approach:

• Reference established molecular weights:

  • FBXW7α: 110kDa

  • FBXW7β: 68-70kDa

  • FBXW7γ: 65-66kDa

  • Bands significantly different from these weights warrant further investigation

• Evaluate potential biological explanations:

  • Higher molecular weight bands: Possible post-translational modifications (ubiquitination, SUMOylation)

  • Lower molecular weight bands: Potential degradation products or splice variants

  • Bands at unrelated weights (e.g., 64kDa): Likely nonspecific detection

• Apply functional validation tests:

  • Proteasome inhibition: True FBXW7 bands should show increased abundance with MG132 treatment

  • Knockdown/knockout verification: Specific bands should decrease or disappear with FBXW7 depletion

  • Research demonstrated that a nonspecific 64kDa band showed no response to MG132 while true FBXW7α at 110kDa increased

• Cross-validate with multiple approaches:

  • Compare detection patterns across multiple antibodies targeting different epitopes

  • Use tagged FBXW7 constructs detected by tag-specific antibodies as reference points

  • Consider immunoprecipitation followed by mass spectrometry for definitive identification

What are common sources of contradictory results when using different FBXW7 antibodies?

Several factors can lead to contradictory results between different FBXW7 antibodies:

• Epitope-specific detection limitations:

  • Research demonstrates that N-terminus antibodies effectively detect FBXW7α in denatured samples, while some C-terminus antibodies fail despite targeting regions common to all isoforms

  • The C-terminus forms a highly organized 3D structure requiring native conformation for recognition by some antibodies

• Antibody specificity issues:

  • Some commercial antibodies may detect nonspecific proteins rather than FBXW7

  • Published research identified a widely used C-terminus antibody that consistently detected a nonspecific 64kDa band instead of any FBXW7 isoform

• Protein regulation differences:

  • True FBXW7 detection should show expected regulatory responses (e.g., increased levels with proteasome inhibition)

  • Nonspecific bands typically show no response to regulatory treatments

  • In research, the nonspecific 64kDa band showed no change with MG132 treatment, while true FBXW7α increased

• Methodology variations:

  • Sample preparation differences (native vs. denaturing conditions)

  • Transfer efficiency variations affecting high molecular weight proteins

  • Blocking reagents that may mask certain epitopes

Understanding these sources of contradiction is essential for proper experimental design and interpretation of results in FBXW7 research.

How can computational approaches enhance FBXW7 antibody selection and validation?

Computational approaches offer powerful tools for improving FBXW7 antibody selection and validation:

• Structural modeling for epitope analysis:

  • AlphaFold and similar structure prediction tools provide insights into FBXW7's 3D structure

  • Research utilized structural prediction to explain why N-terminus antibodies (targeting a linear, disorganized loop) performed better than some C-terminus antibodies (targeting a highly organized β-sheet structure)

  • Homology modeling workflows can predict antibody-antigen interactions and guide epitope selection

• Antibody design and optimization:

  • Computational tools enable de novo CDR loop conformation prediction for improved antibody design

  • Batch homology modeling accelerates model construction for parent sequences and variants

  • Prediction tools help identify and prioritize promising antibody candidates with higher specificity

• Interaction prediction capabilities:

  • Ensemble protein-protein docking predicts antibody-antigen complex structures

  • Fast protein-protein docking identifies favorable antibody-antigen contacts

  • These approaches help predict which antibodies will most effectively bind FBXW7 in different conformational states

• Risk assessment for antibody performance:

  • Computational tools highlight potential surface sites for post-translational modification

  • Detection methods identify potential aggregation hotspots

  • These analyses help researchers select antibodies with lower risk of interference from modifications or structural changes

Integration of these computational approaches with experimental validation leads to more reliable FBXW7 detection and reduces the risk of nonspecific antibody interactions that have compromised previous research .

How can researchers effectively study FBXW7 degradation pathways using antibody-based approaches?

To investigate FBXW7 degradation pathways using antibody-based methods, researchers should implement these approaches:

• Proteasome inhibition studies:

  • Treat cells with proteasome inhibitors (e.g., MG132) at multiple time points

  • Monitor FBXW7 accumulation using validated N-terminus antibodies for FBXW7α

  • Research has demonstrated that MG132 treatment increases the abundance of the 110kDa FBXW7α band detected by N-terminus antibodies, confirming active proteasomal regulation

  • Compare with known FBXW7 substrates (CYCLINE, c-MYC, HIF1α) to establish regulatory relationships

• Ubiquitination analysis:

  • Immunoprecipitate FBXW7 using validated N-terminus antibodies for FBXW7α

  • Probe immunoprecipitates for ubiquitin to detect ubiquitinated FBXW7

  • Include appropriate controls to confirm specific FBXW7 recognition

  • Published research demonstrates successful immunoprecipitation of FBXW7α using N-terminus antibodies, enabling such interaction studies

• Protein stability assessment:

  • Perform cycloheximide chase experiments to determine FBXW7 half-life

  • Use validated antibodies that reliably detect FBXW7 at the correct molecular weight

  • Monitor degradation kinetics across different conditions (e.g., hypoxia, which was used in research)

  • Compare wild-type FBXW7 with mutant versions to identify stability-regulating domains

• Stimulus-response experiments:

  • Expose cells to relevant stimuli like hypoxia (as used in the research)

  • Monitor changes in FBXW7 levels using validated antibodies

  • Correlate with functional outcomes like substrate accumulation

What are the best practices for studying FBXW7 mutations and their effects on protein function?

When investigating FBXW7 mutations and their functional impacts, researchers should follow these evidence-based practices:

• Expression system considerations:

  • Generate tagged wild-type and mutant FBXW7 constructs for reliable detection

  • Use antibodies validated against overexpressed constructs to ensure specific detection

  • Consider both transient and stable expression systems to account for expression level effects

  • Research demonstrates that tagged constructs provide reliable detection of FBXW7 isoforms at their expected molecular weights

• Mutation validation approaches:

  • Confirm mutant protein expression by Western blotting using validated antibodies

  • Verify that detected bands correspond to expected molecular weights (110kDa for FBXW7α)

  • Include domain structure analysis to predict how mutations might affect protein folding and function

• Functional assays:

  • Substrate binding assessment: Compare wild-type and mutant FBXW7 interactions with known substrates

  • Ubiquitination activity: Measure the ability of mutant FBXW7 to promote substrate ubiquitination

  • Subcellular localization: Determine if mutations alter FBXW7 localization patterns

  • Half-life analysis: Assess if mutations affect FBXW7 protein stability

• Structural correlation:

  • Integrate computational structure predictions (e.g., AlphaFold) to interpret mutation effects

  • Research utilized structural prediction to explain antibody epitope accessibility differences

  • Correlate mutation locations with known functional domains and interaction surfaces

• Controls and validation:

  • Include appropriate wild-type controls in all experiments

  • Use multiple detection methods to confirm results

  • Consider rescue experiments to establish causality between mutations and observed phenotypes

These practices ensure reliable characterization of FBXW7 mutations while avoiding the methodological pitfalls identified in published antibody validation studies .

How can researchers leverage antibody engineering advances to improve FBXW7 research tools?

Recent advances in antibody engineering offer significant opportunities to develop improved research tools for FBXW7 studies:

• Structure-guided antibody design:

  • Utilize computational structure prediction to identify optimal epitopes for FBXW7 detection

  • Develop antibodies targeting regions with stable conformation across experimental conditions

  • Apply fully guided homology modeling workflows with de novo CDR loop conformation prediction to design antibodies with improved specificity

  • Research has demonstrated that the structure of FBXW7 domains significantly impacts antibody recognition efficiency

• Enhanced specificity development:

  • Generate antibodies with improved isoform specificity through rational design

  • Utilize computational tools to identify epitopes unique to specific FBXW7 isoforms

  • Apply batch homology modeling to accelerate model construction for parent sequences and variants

  • Employ prediction tools for antibody structure characterization to prioritize promising candidates

• Advanced validation technologies:

  • Implement ensemble protein-protein docking to predict antibody-antigen complex structures

  • Enhance resolution of experimental epitope mapping from peptide to residue-level detail

  • Identify favorable antibody-antigen contacts through fast protein-protein docking

  • These approaches help predict antibody performance before experimental validation

• Risk reduction strategies:

  • Use computational tools to highlight potential surface sites for post-translational modification

  • Detect potential aggregation hotspots using protein surface analysis

  • Predict the impact of residue substitution on binding affinity and specificity

  • These approaches help develop antibodies less susceptible to the issues identified in previous FBXW7 research

Integration of these advanced approaches addresses the significant challenges in FBXW7 antibody specificity documented in research, where widely used antibodies were found to detect nonspecific targets rather than actual FBXW7 protein .

How might single-cell analysis techniques transform our understanding of FBXW7 expression patterns?

Single-cell analysis technologies offer revolutionary potential for understanding FBXW7 biology:

• Single-cell protein detection advantages:

  • Reveal cell-to-cell heterogeneity in FBXW7 expression masked in bulk analyses

  • Identify rare cell populations with distinct FBXW7 expression patterns

  • Correlate FBXW7 levels with cell cycle state and differentiation status at single-cell resolution

  • These approaches would extend beyond the bulk analysis limitations of current Western blotting methods

• Implementation strategies:

  • Single-cell Western blotting using validated antibodies to quantify FBXW7 isoforms

  • Mass cytometry (CyTOF) with metal-conjugated FBXW7 antibodies for high-dimensional analysis

  • Imaging mass cytometry to preserve spatial context while quantifying FBXW7 levels

  • Microfluidic antibody capture for sensitive FBXW7 quantification

• Validation requirements:

  • Rigorous antibody validation is particularly critical for single-cell applications

  • Cross-validation with orthogonal methods (e.g., RNA sequencing, fluorescent protein tagging)

  • Research findings regarding antibody specificity issues highlight the importance of thorough validation before single-cell implementation

• Integration with multi-omics:

  • Combine single-cell FBXW7 protein detection with transcriptomics and metabolomics

  • Correlate FBXW7 levels with substrate abundance at single-cell resolution

  • These integrated approaches would provide unprecedented insights into FBXW7 regulation and function

These technologies could revolutionize our understanding of how FBXW7 expression varies across cell populations and states, providing insights impossible with current bulk analysis methods while requiring careful consideration of the antibody validation challenges identified in research .

What are the emerging applications of FBXW7 antibodies in clinical research?

Emerging clinical applications of FBXW7 antibodies include:

• Diagnostic and prognostic biomarker development:

  • FBXW7 mutations and expression changes are associated with various cancers

  • Validated antibodies could enable immunohistochemical assessment of FBXW7 status in patient samples

  • Correlation of FBXW7 levels with patient outcomes could identify prognostic signatures

  • Research has demonstrated the importance of using thoroughly validated antibodies to avoid misleading clinical correlations

• Therapeutic response prediction:

  • FBXW7 status may predict sensitivity to targeted therapies and proteasome inhibitors

  • Antibody-based methods could stratify patients for clinical trials based on FBXW7 expression

  • Monitoring FBXW7 levels during treatment might provide early indicators of therapeutic efficacy

  • Such applications require antibodies with confirmed specificity against actual FBXW7 protein

• Companion diagnostic development:

  • As therapies targeting FBXW7-regulated pathways emerge, companion diagnostics using validated antibodies could guide treatment decisions

  • Multiplex immunohistochemistry could assess FBXW7 alongside its substrates to provide comprehensive pathway evaluation

  • These applications demand rigorous antibody validation to ensure accurate patient classification

• Monitoring disease progression:

  • In conditions with FBXW7 involvement, such as systemic sclerosis overlap syndrome where autoantibodies play a role, monitoring FBXW7 and related autoantibodies could track disease activity

  • Research in systemic sclerosis has shown that autoantibodies are associated with clinical features, organ involvement, and prognosis

These clinical applications emphasize the critical importance of antibody validation highlighted in research, where nonspecific antibody detection could lead to incorrect clinical correlations and potentially misinformed treatment decisions .

How will integrated computational and experimental approaches transform FBXW7 antibody development?

The integration of computational and experimental approaches is poised to revolutionize FBXW7 antibody development:

• AI-enhanced epitope selection:

  • Machine learning algorithms trained on successful antibody-antigen interactions can identify optimal FBXW7 epitopes

  • Structural prediction tools like AlphaFold provide insights into FBXW7's 3D conformation for epitope accessibility analysis

  • Research has utilized structural prediction to explain why certain antibody epitopes (like the N-terminus) yield more reliable detection than others (C-terminus)

  • These approaches help avoid the pitfalls identified in previous FBXW7 antibody development

• Rational antibody design pipeline:

  • Computational structure-based design identifies promising antibody candidates

  • High-throughput experimental validation screens confirm in silico predictions

  • Iterative refinement through machine learning from experimental results

  • These methods enable development of antibodies with improved specificity for challenging targets like FBXW7

• Advanced validation technologies:

  • Predicting antibody-antigen complex structures through ensemble protein-protein docking

  • Enhancing resolution of experimental epitope mapping from peptide to residue-level detail

  • Identifying favorable antibody-antigen contacts through fast protein-protein docking

  • These approaches provide more comprehensive validation than traditional methods

• Performance optimization capabilities:

  • Accurately predicting how residue substitutions impact binding affinity and specificity

  • Rapidly identifying high-quality protein variants through computational scanning

  • Refining antibody candidates using methods that reproduce experimentally determined binding energies

  • These tools enable systematic optimization rather than trial-and-error approaches

This integration addresses the significant challenges in FBXW7 antibody specificity documented in research, where commonly used antibodies failed to detect their intended targets, compromising research findings and highlighting the need for improved development and validation approaches .